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Abstract
 .In this study we characterized the IgG antibodies against lipopolysaccharides LPS of Campylobacter jejuni in serum from patients
 .  .with Guillain-Barre syndrome GBS , Miller Fisher syndrome MFS , C. jejuni enteritis and normal controls. In patients with GBS and´
MFS long-lasting titers of IgG1 and IgG3 antibodies against LPS from GBS and MFS associated C. jejuni were found. The subclass and
course of these antibodies were highly associated with those of antibodies against GM1 and GQ1b in GBS and MFS patients. However, in
C. jejuni enteritis and normal controls anti-LPS antibodies were predominantly IgG2. Antibody binding with LPS was reduced after
treatment with choleratoxin and sialidases, suggesting that the ganglioside-like epitopes in LPS are immunodominant. These results
further indicate that antecedent C. jejuni infections determine the specificity and isotype of anti-ganglioside antibodies in GBS and MFS
patients. q 1997 Elsevier Science B.V.
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1. Introduction
 .The Guillain-Barre syndrome GBS is an acute´
monophasic polyneuropathy leading to a heterogeneous
spectrum of motor and sensory deficits Van der Meche´
.  .and Van Doorn, 1995 . The Miller Fisher syndrome MFS ,
characterized by ophthalmoplegia, areflexia and ataxia, is
considered to be one of its variants. GBS and MFS may
result from a transient immune response against peripheral
nerves, triggered by an infection which often preceeds the
neurological onset.
Campylobacter jejuni is a frequent cause of antecedent
 . infections in GBS Rees et al., 1995a , and MFS Yuki et
.al., 1994; Jacobs et al., 1995 . These infections are associ-
ated with the presence of antibodies against gangliosides in
patients with GBS Walsh et al., 1991; Rees et al., 1995b;
. Jacobs et al., 1996 and MFS Yuki et al., 1994; Jacobs et
.al., 1995 . Anti-GM1 antibodies are associated with severe
) Corresponding author. Tel.: q31-10-4088209; fax: q31-10-4367085.
 .motor involvement in GBS Jacobs et al., 1995 and
anti-GQ1b antibodies with MFS and oculomotor involve-
 .ment in GBS Chiba et al., 1993 . The high concentration
of GM1 in myelin of motor nerves Ogawa-Goto et al.,
. 1992 and of GQ1b in oculomotor nerves Chiba et al.,
.1993 reflects these clinical manifestations. These antibod-
ies may be induced by the infection, since ganglioside-like
 .epitopes are found in lipopolysaccharides LPS of C.
 .jejuni isolates from patients with GBS Yuki et al., 1993
 .and MFS Salloway et al., 1996 . Furthermore, anti-GM1
IgG antibodies from GBS patients cross-react with GBS
 .associated C. jejuni Oomes et al., 1995 , and anti-GQ1b
IgG antibodies with MFS associated isolates Yuki et al.,
.1994; Jacobs et al., 1995 .
Two issues considering the cross-reactivity of anti-LPS
antibodies in GBS need to be clarified. Firstly, in approxi-
mately half of the GBS patients with C. jejuni infections
no antibodies against gangliosides are found Walsh et al.,
.1991; Rees et al., 1995b; Jacobs et al., 1996 . These
patients may have LPS induced antibodies which cross-re-
act with other peripheral nerve antigens. So far, antibodies
against C. jejuni LPS were investigated only in small
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groups of GBS patients with anti-GM1 antibodies, but not
in GBS patients without these antibodies.
Secondly, ganglioside-like epitopes are also demon-
strated in C. jejuni isolates from enteritis patients without
GBS or MFS Aspinall et al., 1993; Yuki et al., 1994;
.Jacobs et al., 1995 . This indicates that, in addition to the
fine-specificity, other features of the cross-reactive anti-
bodies determine their possible pathogenicity. The subclass
may be important since it determines the effector functions
of the antibodies. In general, IgG antibodies against bacte-
rial polysaccharides are predominantly of the IgG2 sub-
 .class Hammerstrom and Smith, 1986 . Antibodies against¨
gangliosides in GBS and MFS patients, however, are
predominantly IgG1 and IgG3 Willison and Veitch, 1994;
.Ogino et al., 1995; Yuki et al., 1995 . So far, a compara-
tive study on the IgG subclasses of anti-LPS antibodies in
patients with GBS, and in C. jejuni enteritis without GBS
has not been performed.
To further characterize the humoral immune response
against C. jejuni LPS, we studied the presence, course,
subclass distribution and specificity of serum IgG antibod-
ies against C. jejuni LPS in a large and heterogeneous
group of GBS and MFS patients, compared to patients
with C. jejuni enteritis and normal controls.
2. Patients and methods
2.1. C. jejuni isolates and lipopolysaccharides
C. jejuni was isolated from 3 patients with MFS A, B
.  .and C , 3 patients with GBS D, E and F and 3 enteritis
 .controls without neurological involvement 1, 2 and 3 .
Patients A–E and 1–3 and their C. jejuni isolates were
described previously Jacobs et al., 1995; Jacobs et al., in
.press . Patients A, B and C suffered from ophthalmoplegia,
ataxia and areflexia without limb weakness, and patients
D, E and F fulfilled the diagnostic criteria for GBS As-
.bury and Cornblath, 1990 . Serum anti-ganglioside anti-
bodies were found in MFS patient A and C GQ1b, GD1b,
.  .  .GD3 , B GQ1b and GBS patient D GM1, GD1b , but
not in GBS patient E. Serum from GBS patient F and
enteritis controls 1–3 was not available. The C. jejuni
isolates were serotyped according to the Penner classifica-
tion system, which is based on the bacterial LPS, as O:4,50
 .  .  .  .A , non-typable B and F , 0:23 C and 1 , O:1 D , O:24
 .  .  .E , O:22 2 and O:41 3 . C. jejuni was grown for 48 h
on blood agar plates in a microaerobic atmosphere, inacti-
vated in 1% formaldehyde and washed in phosphate-
 .  .buffered saline solution PBS pH 7.4 . The LPS fractions
from C. jejuni were isolated by phenol–water extraction
 .Westphal and Jann, 1965 and were demonstrated to
contain less than 1% protein.
2.2. Sera from GBS, MFS and control patients
Serum samples from 41 GBS patients, 3 MFS patients,
 .12 C. jejuni enteritis controls CJC without neurological
 .involvement, and 12 normal controls NC were tested for
IgG antibodies against LPS. The patients were subdivided
into 6 groups depending on the presence of antibodies
against GM1 or GQ1b and antecedent C. jejuni infection
 .Table 1 . Recent C. jejuni infections were serologically
defined as the presence of IgM, IgA, or high titers of IgG
antibodies against C. jejuni in ELISA, as previously de-
 .scribed Jacobs et al., 1996 . The CJC had diarrhea and a
positive C. jejuni serology. The samples from the GBS and
MFS patients were obtained within 2 weeks of neurologi-
cal symptoms and before treatment. All sera were tested
for antibodies against the gangliosides GM1, GM3, GD1a,
GD1b, GD3, GT1b and GQ1b, by enzyme linked im-
 .munoadsorbent assay ELISA and thin-layer chromatogra-
phy overlay, according to methods described previously
 .Jacobs et al., 1996 .
2.3. Detection of antibodies against lipopolysaccharides
Serum antibodies against LPS were tested in ELISA, by
coating 96-well polystyrene microtiter trays Immuno
.Maxisorb, Roskilde with 1 mg of LPS in 50 ml PBS per
well overnight at 378C. Unspecific binding sites were
blocked for 4 h with PBS containing 1% bovine serum
Table 1
Anti-ganglioside antibodies and C. jejuni infections in patients tested for antibodies against C. jejuni lipopolysaccharides
aGroup Patients IgG antibodies C. jejuni infection Including patient
number diagnosis GM1 GQ1b
 .1 12 GBS 12 0 9 75% D
 .2 8 GBSrMFS 0 8 5 63% A, B and C
 .3 12 GBS 0 0 12 100% E
4 12 GBS 0 0 0
 .5 12 CJC 0 0 12 100%
6 12 NC 0 0 0
Total 68 12 8 38
GBS, Guillain-Barre syndrome; MFS, Miller Fisher syndrome; CJC, C. jejuni enteritis control without neurological involvement; NC, normal control.´
a  .Defined as positive C. jejuni serology Jacobs et al., 1996 .
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 .  .albumine BSA Sigma, St. Louis, MO . After blocking,
the plates were incubated overnight at 48C with serum
diluted 1:1000 in PBS–1% BSA. After washing with PBS,
the plates were incubated with peroxidase-conjugated goat
 .  .antihuman IgG g-chain specific Sigma , diluted 1:2500
in PBS–1% BSA, for 90 min at room temperature. After
washing with PBS, the plates were developed with O-
 .  .phenyl diamine Sigma in citrate buffer pH 5.0 and the
 .optical densities ODs were read at 490 nm. All samples
were assayed in duplicate. The serum was tested in both
LPS-coated and blank wells, allowing the OD values to be
calculated after subtraction of the blank well OD from the
coated-well OD. Serum samples with ODs of more than 3
SD above the mean value of 12 NC sera were considered
to be of high titer, and were further tested to determine the
IgG subclasses. These samples were diluted 1:250 in PBS–
1% BSA and tested according to the same protocol. Sub-
classes were identified by using peroxidase-conjugated
 .monoclonal goat antihuman IgG1 clone MH161-1 , IgG2
 .  . clone HP6014 , IgG3 clone MH163-1 and IgG4 clone
.  .MH164-4 CLB, Amsterdam diluted 1:100, 1:200, 1:200
and 1:200 in PBS–1% BSA, respectively. All serum sam-
ples were also tested for IgG1 and IgG2 antibodies against
 .Pneumovax Merck, Sharp and Dohme, Haarlem , a mix-
ture of capsular polysaccharides from 23 different serotypes
of Streptococcus pneumoniae, by routine techniques.
2.4. Sialidase treatment of lipopolysaccharides
The LPS fractions were incubated with 0.05 Urml of
 .  .sialidase from Clostridium perfringens CP Sigma or
 .  .Arthrobacter ureafaciens AU Sigma in 50 mM of
 .sodium acetate buffer pH 5.5 overnight at 378C. After
incubation, the LPS were incubated at 808C for 30 min to
inactivate the sialidases. In control studies, the LPS were
incubated in the same conditions without sialidases. Anti-
bodies against the desialylated LPS were further tested
according to the method described in Section 2.3.
2.5. Cholera toxin treatment of lipopolysaccharides
The LPS fractions were coated according to the proto-
col described in 2.3, and incubated with 25 mgrml of B
 .  .subunit of cholera toxin CT Sigma in PBS–1% BSA
overnight at 48C. The plates were emptied before further
testing. In control studies, the LPS were incubated in the
same conditions without CT. Antibodies against the CT
blocked LPS were further tested according to the method
described in Section 2.3.
3. Results
3.1. IgG antibodies against LPS
 .  .In the anti-GM1 positive patients group 1 , 9 75% of
12 patients had high IgG activity against LPS of C. jejuni
isolates from MFS patient A, GBS patients D, E and F, or
 .control 3 Fig. 1 . Six patients had IgG antibodies against
all these isolates, 2 only against the 3 GBS associated
isolates and 1 only against GBS related isolate F. All these
patients with anti-LPS antibodies had a recent C. jejuni
 .  .Fig. 1. Serum IgG activity against LPS from C. jejuni isolates from MFS patients A, B, C , GBS patients D, E, F , and enteritis controls without
 .neurological involvement 1, 2, 3 . The patients tested for IgG activity were subdivided into 6 groups according to diagnosis, presence of anti-ganglioside
 .infections and antecedent C. jejuni infections see Table 1 .
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infection. The 3 patients without anti-LPS activity had no
C. jejuni infection and 2 had lower anti-GM1 IgG titers
than 1:1000. No evident difference in additional IgG activ-
ity against other gangliosides was found in the patients
with anti-LPS IgG antibodies compared to those without.
However, the 6 patients with IgG against the C. jejuni
isolate A all had additional anti-GD1b antibodies data not
.shown .
 .  .In the anti-GQ1b positive patients group 2 , 6 75% of
8 patients had high IgG activity against LPS of C. jejuni
 .isolates from MFS patients A, B or C Fig. 1 . IgG activity
against at least 2 of these isolates was found in 5 patients.
Four of the patients with anti-LPS antibodies had a recent
C. jejuni infection. No difference was found in anti-GQ1b
IgG titer or antibodies against other gangliosides between
patients with anti-LPS antibodies compared to those with-
out. In the anti-GM1rGQ1b negative GBS patients, high
 .IgG activity against LPS was found only in 1 8% of the
 .12 patients with C. jejuni infection group 3 , which was
to LPS from control isolate 3, and in none of the 12
 .  .patients without this infection group 4 Fig. 1 . Two
 .17% of the 12 C. jejuni infected controls without GBS or
 .  .MFS group 5 , and 1 8% of the 12 normal controls
 .group 6 had high anti-LPS IgG activity. The IgG in these
patients reacted with LPS from the MFS associated iso-
 .lates B and C Fig. 1 .
In GBS patients with high anti-LPS activity follow-up
samples obtained at 3 or 6 months were also tested. The
anti-LPS IgG activity in these samples was lower than in
pretreatment samples, although the activity was still higher
than in normal controls. The antibody activity against LPS
showed a similar course as the activity against ganglio-
 .sides in individual patients Fig. 2 .
Fig. 2. Follow-up of IgG antibody activity against LPS of 3 GBS
 .  .associated C. jejuni isolates D, E, F expressed as extinctions and of
 .anti-GM1 IgG activity expressed as titers in two GBS patients with C.
 .jejuni infection, one treated with intravenous immunoglobulins A , and
 .one with plasma exchange B .
Table 2
Subclasses of IgG antibodies against GM1, GQ1b and C. jejuni LPS in
serum from patients with GBS, MFS, and CJC and NC with high titers of
anti-LPS antibodies
aGroup Patient GM1 GQ1b Lipopolysaccharides
MFS GBS Control
A B C D E F 3
GBS 1 1 — — — — 1 1 1, 3 1
2 1 — 1 — — 1 1 1 1
3 3, 1 — 3, 1 — — 3, 1 3, 1 3, 1 3, 1
4 1 — 1 — — 1 1 1 1
5 1 — 1 — — 1 1 1 1
6 1 — — — — 1 1 1 1
7 1, 3 — 1 — — 1 1 1, 3 1
8 1 — 1 — — 1 1 1, 3 1
9 1 — — — — — — 1 —
10 — — — — — — — — 1
GBSrMFS 11 — 3, 1 3, 1 — 3, 1 — — — —
12 — 1 1 — — — — — —
13 — 3 — 3 3 — — — —
14 — 3, 1 3, 1 3, 1 3, 1 — — — —
15 — 3 — 1 3, 1 — — — —
16 — 3 — 3, 1 3, 1 — — — —
CJC 17 — — — 2 2 — — — —
18 — — — 2 2 — — — —
NC 19 — — — 2, 1 2 — — — —
GBS, Guillain-Barre syndrome; MFS, Miller Fisher syndrome; CJC, C,´
jejuni enteritis control without neurological involvement; NC, normal
control.
a  .LPS from C. jejuni isolates from MFS patients A, B, C , GBS patients
 .  .D, E, F and an enteritis control without neurological involvement 3 .
Numbers 1 to 4 refer to the presence of subclasses IgG1 to IgG4,
respectively, with the first mentioned being the predominant subclass.
Axonal degeneration, as indicated by the presence of
 .denervation potentials, was found in 5 50% of 10 patients
 .  .in group 1, 2 25% of 8 patients in group 2, 2 20% of 10
 .patients in group 3, and 1 9% of 11 patients in group 4.
No clear association between the presence of anti-LPS
antibodies and axonal degeneration could be demonstrated.
3.2. Subclasses of IgG antibodies against gangliosides and
LPS
The subclass of the IgG antibodies against GM1, GQ1b
and LPS were determined in all patients with high IgG
activity against LPS, and are given in Table 2. IgG anti-
bodies against GM1 or GQ1b were all of the IgG1 or IgG3
subclasses. In most patients the predominant isotype of
anti-GM1 antibodies was IgG1, and of anti-GQ1b antibod-
ies was IgG3. In GBS and MFS patients the IgG antibodies
against LPS were also of the IgG1 or IgG3 subclasses and
generally corresponded with the isotype of the anti-gang-
 .lioside antibodies in individual patients Table 2 . How-
ever, in serum from CJC and NC, antibodies against LPS
from C. jejuni isolates B and C were predominantly IgG2.
Control studies demonstrated that IgG2 antibodies against
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 .Fig. 3. Serum IgG activity against LPS preincubated with neuraminidase from Clostridium perfringens in 50 mM sodiumacetate buffer CPq , 50 mM
 .  .  .sodiumacetate buffer only CPy , cholera toxin in PBS–1% BSA CTq , or PBS–1% BSA only CTy . These experiments were performed with LPS
 .  .  .of C. jejuni from GBS patient E A , MFS patient B B , and MFS patient A C . Serum was tested from all patients with antibodies against these LPS.
pneumococcal polysaccharides were present in all patients
 .and controls data not shown .
3.3. Specificity of IgG antibodies against LPS
To further characterize the specificity of the anti-LPS
antibodies, we incubated the LPS with sialidases and CT.
Binding of IgG to C. jejuni isolate E in serum from
anti-GM1 positive patients was reduced to baseline after
 .blocking the LPS with CT Fig. 3A . Treatment of the LPS
with sialidase CP had no or an increasing effect on the
 .antibody binding Fig. 3A . The same results were found
with LPS from C. jejuni isolates D, F and 3 data not
.shown .
Treatment of LPS from C. jejuni isolate B with siali-
dase CP reduced the binding of IgG to LPS in serum from
 .the anti-GQ1b positive patients, CJC and NC Fig. 3B .
The reactivity was not influenced by blocking the LPS
with CT. The same results were found with LPS from C.
 .jejuni isolate C data not shown . In LPS from C. jejuni
 .isolate A a combination of effects was found Fig. 3C .
After blocking with CT the IgG binding to LPS was
reduced in anti-GM1 positive patients, but not in anti-GQ1b
positive patients. After treatment with sialidase CP, the
IgG binding was reduced in anti-GQ1b positive patients
but not in anti-GM1 positive patients. Sialidases from CP
and AU gave similar results in all experiments.
4. Discussion
The present study demonstrates that the IgG responses
against C. jejuni LPS and gangliosides are closely associ-
ated in patients with GBS and MFS. Firstly, high IgG
activity against LPS from GBS related C. jejuni isolates
was found in anti-GM1 positive GBS patients. Anti-GQ1b
positive GBS and MFS patients had high titers of IgG
against LPS from the MFS related strains. Secondly, the
titer course and subclass of the IgG antibodies against LPS
corresponded with those of the antibodies against GM1
and GQ1b. Such a similarity in subclass distribution was
 .also found by others Yuki et al., 1995 . Thirdly, the
antibody binding with LPS in sera with anti-GM1 or
anti-GQ1b antibodies was reduced to baseline after CT and
sialidase treatment of the LPS, respectively. These findings
suggest that most of the anti-LPS IgG activity in GBS and
MFS patients is due to antibodies against ganglioside-like
epitopes in LPS, indicating that these epitopes are immun-
odominant in a humoral immune response against LPS.
This further supports the hypothesis that antecedent C.
jejuni infections in GBS and MFS trigger the production
of cross-reactive antibodies against gangliosides.
Molecular mimicry between gangliosides and LPS has
been demonstrated with C. jejuni isolates from GBS and
 .MFS patients Yuki et al., 1993; Salloway et al., 1996 .
Previously we found that anti-GQ1b antibodies cross-react
with LPS of C. jejuni from MFS patient A, B and C, and
anti-GM1 antibodies with C. jejuni from GBS patient E
 .and control 3 Jacobs et al., 1997 . In the present study we
demonstrate that anti-LPS antibodies in C. jejuni infected
GBS patients without anti-ganglioside antibodies are rare.
This indicates that, except for these ganglioside-like epi-
topes, other LPS structures do not induce cross-reactive
antibodies. However, C. jejuni infection in these patients
may induce cross-reactive antibodies against bacterial
structures other than LPS. This is supported by the finding
that antibodies against peripheral nerve proteins are in-
duced by immunization with C. jejuni proteins in animals
 .Fujimoto and Amako, 1990; Kaldor et al., 1992 .
In some patients with anti-ganglioside antibodies we did
not find high IgG activity against LPS. This may result
from relatively low titers or different fine-specificities of
the anti-ganglioside antibodies in these patients. In previ-
ous studies we found no binding of anti-GM1 antibodies
with LPS of C. jejuni from MFS patient A and GBS
 .patient D Jacobs et al., 1997 . In the present study we
demonstrated antibodies against these isolates in a sub-
group of the anti-GM1 positive patients. These patients all
had additional antibody activity against GD1b, suggesting
that the antibodies recognize the shared Gal b 1–
.3 GalNAc-moiety on GM1 and GD1b. The antibodies may
also react with this moiety in LPS, since the antibody
binding was insensitive to sialidases and could be blocked
by CT. This is in accordance with the finding that CT also
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 .binds with Gal b 1–3 GalNAc-containing glycolipids other
 .than GM1 Schwerer et al., 1995 .
In the present study we found antibodies against LPS
from MFS associated C. jejuni in serum from enteritis and
normal controls too. These antibodies are probably di-
rected against ganglioside-like epitopes as well, since siali-
dase treatment of the LPS reduced the antibody binding.
Accordingly, ganglioside-like structures were also demon-
strated in C. jejuni from patients without neurological
 .involvement Aspinall et al., 1993 . Our study suggests
that these structures may also be immunodominant in
uncomplicated C. jejuni infections. However, these epi-
topes induce antibodies with other specificities than in
GBS and MFS patients, as indicated by the lack of activity
against GM1 and GQ1b in controls.
The anti-LPS antibodies further differ with respect to
their subclasses in GBS and MFS patients compared to
controls. We found high titers of anti-LPS IgG antibodies
in serum from some enteritis patients and normal controls,
which were predominantly IgG2. The presence of IgG1
and IgG3 antibodies against LPS in GBS and MFS pa-
tients, suggests that in these patients humoral immune
responses against polysaccharides differ from others. The
presence of IgG2 antibodies against pneumococcal capsu-
lar polysaccharides in all GBS and MFS patients excludes
an IgG2 subclass deficiency, and may indicate that the
IgG1 and IgG3 response are restricted to LPS from spe-
cific C. jejuni strains.
Long-lasting, high titers of IgG1 and IgG3 antibodies
are characteristic for T cell dependent immune responses
 .Papadea and Check, 1989 . The role of T cells in the in
vivo production of antibodies against LPS and ganglio-
sides in humans, has not yet been elucidated. In vitro
studies indicate that the production of antibodies against
both bacterial polysaccharides and gangliosides are stimu-
lated in the presence of activated T cells Ambrosino et al.,
.1990; Heidenreich et al., 1994 . In the immune response
against LPS, C. jejuni may induce T cell activation by the
production of a protein that binds to LPS, serving as a
carrier protein for T cell help Willison and Kennedy,
.1993 . A candidate for this protein may be enterotoxins,
which specifically bind with gangliosides and are produced
by specific C. jejuni strains Klipstein and Engert, 1984;
.Suzuki et al., 1994 . If one C. jejuni strain expresses both
this enterotoxin and ganglioside-like LPS, the enterotoxin
may bind to LPS, providing an epitope for T cells. These
activated T cells may skew B cells against LPS to switch
to IgG1 and IgG3 production.
This subclass switch may be crucial for the patho-
genicity of anti-ganglioside antibodies in GBS and MFS.
IgG1 and IgG3 antibodies are more effective than IgG2 in
activating the classical complement pathway Feinstein et
.al., 1986 . Interestingly, the suppression of sodium current
in sciatic nerve by rabbit anti-GM1 antibodies was found
 .to be complement-dependent Takigawa et al., 1995 . In
addition, IgG1 and IgG3 have a higher affinity for Fc
receptors which play a role in opsonization and phago-
 .cytosis Van de Winkel and Capel, 1993 .
In conclusion, our study gives further support to the
hypothesis that infections with specific C. jejuni strains
induce cross-reactive IgG1 and IgG3 antibodies against
LPS and gangliosides in GBS and MFS patients. Further
research is necessary to elucidate the mechanism by which
C. jejuni determines the specificity and isotypes of the
anti-ganglioside antibodies.
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